Pharmaceutical

Menarini signs agreement for Astellas’s rheumatoid arthritis therapy

Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.

Sep 13, 2023 - 20:00
Menarini signs agreement for Astellas’s rheumatoid arthritis therapy
Menarini Asia-Pacific has entered a long-term exclusive agreement to license Astellas Pharma’s Smyraf to treat rheumatoid arthritis.
Read the original article

Tags:

Previous Article

Signal: Roche to refile subcutaneous Tecentriq with FDA after UK approval

Next Article

Dewpoint and Chemify partner for cancer drug discovery

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Valneva seeks Health Canada approval for chikungunya vaccine

Valneva seeks Health Canada approval for chikungunya va...

May 30, 2023

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT+: FTC warns drugmakers they can face legal action ...

Sep 14, 2023

FDA grants fast track designation for Verastem’s NSCLC therapy

FDA grants fast track designation for Verastem’s NSCLC ...

Jan 19, 2024